The truth is that if you invest for long enough, you're going to end up with some losing stocks. But long term...
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its two novel, oral host-directed investigational drugs, opaganib[1] and RHB-107 (upamostat)[2], demonstrated robust synergistic effect when combined individually with remdesivir (Veklury®)[3], significantly improving viral inhibition while maintaining cell viability, in a new U.S. Army-funded and conducted Ebola virus in vitro study.
It hasn't been the best quarter for Heidelberg Pharma AG ( ETR:HPHA ) shareholders, since the share price has fallen...